Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.

Stomper J, Ihorst G, Suciu S, Sander PN, Becker H, Wijermans PW, Plass C, Weichenhan D, Bissé E, Claus R, Lübbert M.

Haematologica. 2019 Jan;104(1):59-69. doi: 10.3324/haematol.2017.187278. Epub 2018 Aug 31.

2.

Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma.

Anglin J, Zavareh RB, Sander PN, Haldar D, Mullarky E, Cantley LC, Kimmelman AC, Lyssiotis CA, Lairson LL.

Bioorg Med Chem Lett. 2018 Sep 1;28(16):2675-2678. doi: 10.1016/j.bmcl.2018.04.061. Epub 2018 Apr 27.

PMID:
29731362
3.

Dinosaur origin of egg color: oviraptors laid blue-green eggs.

Wiemann J, Yang TR, Sander PN, Schneider M, Engeser M, Kath-Schorr S, Müller CE, Sander PM.

PeerJ. 2017 Aug 29;5:e3706. doi: 10.7717/peerj.3706. eCollection 2017.

4.

Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).

Lübbert M, Ihorst G, Sander PN, Bogatyreva L, Becker H, Wijermans PW, Suciu S, Bissé E, Claus R.

Br J Haematol. 2017 Feb;176(4):609-617. doi: 10.1111/bjh.14463. Epub 2016 Dec 1.

PMID:
27905102

Supplemental Content

Loading ...
Support Center